Magnisense R&D expands its technology portfolio with MIAplex®, a technology enabling multiparametric assays using magnetic beads as labels
Paris July 24, 2008 -- Magnisense, a developer of next generation bioassays for human and animal diagnostics, food safety and environmental protection, announces today that Luc Lenglet, president of Magnisense, will present a paper on magnetic immunoassays and multiparametric testing, at the annual congress of the American Association for Clinical Chemistry (AACC) in Washington, DC, July 29-31, 2008.
The presentation will take place on Wednesday July 30 at 8.50am. In his paper, Lenglet will show how Magnisense has, for the first time ever, proven the feasibility of multiparametric assays using magnetic beads as labels. The advantages of magnetic beads as labels for bioassays are now becoming widely known. They include intrinsic ability for quantification, time and temperature stability, easy transduction, commercial availability, and low limit of detection. But their usage as labels for multiparametric testing has never been reported till now.
Lenglet will reveal how Magnisense has shown the way a set of magnetic beads differing by their magnetic properties can be used for the investigation of a single sample potentially containing a plurality of targets, with no need for aliquoting. Not only does it then become possible to detect the presence or the absence of each target, but also to quantify each target. The MIAplex™ technology can be embodied in several formats including well-known lateral flow membranes. Several families of magnetic materials have already been identified.
About Magnisense
Magnisense develops and markets magnetic immunoassays. These next-generation bioassays improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing. They are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods.
Exploiting a unique feature of magnetic bead markers, Magnisense’s MIAtek(TM) technology provides true quantification of a large volume sample. The magnetic signal is free of interference from environmental factors, permitting a more sensitive and reproducible detection than possible with other surface-restricted approaches common in lateral flow rapid testing.
Magnisense is developing two test formats for different application areas:
MIAstrip(TM): Point of care testing with a single dose, producing objective, quantifiable and traceable results via a portable reader. MIAstrip enables the identification of a target via detection of known markers for a number of diseases including avian flu, cardiac disease, tetanus, and bacterial, viral, parasitic or mycotic infections.
MIAflo(TM): Disposable cartridges for detection of targets, such as bacterial contamination in food products, e.g. Listeria and Salmonella, or in water, e.g. Legionella, with a sensitivity that brings a significant reduction in testing time.
Founded in 2003, Magnisense has raised two rounds of financing for a total of EUR 6 million from Baring Vostok Capital Partners and private investors.
For further information: www.magnisense.com
| Press and Analyst contacts: Andrew Lloyd & Associates - +44 1273 675 100 Andrew Lloyd – Neil Hunter allo@ala.com - neil@ala.com |